RxDoctor Payments DataLook up a doctor →

Robert Wollenzien

Physician Assistant · Salem, UTNPI 1831674092

Payments from drug & device makers

$9,281in general payments, 2019–2025

Across 735 payments — averaging $12.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$995
  • AstraZeneca$727
  • Astellas Pharma US Inc$628
  • Lilly USA, LLC$625
  • Boehringer Ingelheim$398
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$9,281100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,281 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$113,489
Medicare patients
413
Services billed
3,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$132,499
JardianceEmpagliflozin91$116,912
EliquisApixaban108$114,274
MounjaroTirzepatide73$94,583
FarxigaDapagliflozin Propanediol59$66,970
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog34$34,249
TrulicityDulaglutide32$31,566
Soliqua 100-33Insulin Glargine/Lixisenatide25$31,093
MyrbetriqMirabegron21$20,256
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$20,159
Synjardy XrEmpagliflozin/Metformin Hcl17$15,939
XareltoRivaroxaban12$13,961
GemtesaVibegron18$13,002
Omeprazole355$7,894
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$6,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$398$132,851108 claims
Novo NordiskOzempic$995$132,499109 claims
Lilly USA, LLCMounjaro, Trulicity$625$126,150105 claims
PfizerEliquis$340$114,274108 claims
AstraZenecaFarxiga$727$66,97059 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$174$31,09325 claims
Astellas Pharma US IncMyrbetriq$628$20,25621 claims
GSKTrelegy Ellipta$141$20,15934 claims
Johnson & JohnsonXarelto$140$13,96112 claims
Sumitomo Pharma America, Inc.Gemtesa$50$13,00218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Salem

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →